Hexagon Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Hexagon Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-69	Closed	-$33.5K	–	1681
2025 Q1	$33.5K	Sell	69 -4	-5%	-$1.86K	0.01%	586
2024 Q4	$29.4K	Sell	73 -50	-41%	-$23.2K	0.01%	649
2024 Q3	$57.2K	Sell	123 -13	-10%	-$6.25K	0.01%	424
2024 Q2	$63.7K	Sell	136 -2	-1%	-$868	0.01%	380
2024 Q1	$57.7K	Buy	138 +59	+75%	+$24.9K	0.01%	399
2023 Q4	$32.1K	Buy	79 +2	+3%	+$739	0.01%	516
2023 Q3	$26.8K	Hold	77	–	–	0.01%	488
2023 Q2	$27.1K	Hold	77	–	–	0.01%	484
2023 Q1	$24.3K	Hold	77	–	–	0.01%	500
2022 Q4	$22.2K	Sell	77 -63	-45%	-$19.2K	0.01%	517
2022 Q3	$41K	Hold	140	–	–	0.01%	429
2022 Q2	$39K	Hold	140	–	–	0.01%	417
2022 Q1	$37K	Hold	140	–	–	0.01%	410
2021 Q4	$31K	Hold	140	–	–	0.01%	431
2021 Q3	$25K	Sell	140 -87	-38%	-$17K	0.01%	455
2021 Q2	$46K	Buy	227 +8	+4%	+$1.67K	0.01%	341
2021 Q1	$47K	Hold	219	–	–	0.01%	317
2020 Q4	$51K	Hold	219	–	–	0.02%	267
2020 Q3	$45K	Buy	+219	New	+$60.4K	0.01%	267

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Hexagon Capital Partners's VRTX Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 69 shares — an estimated $33.5K sold.

Hexagon Capital Partners first reported a position in VRTX in Q3 2020 and held it in 19 quarters. The position peaked at $63.7K in Q2 2024. 1,563 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Hexagon Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 69 Vertex Pharmaceuticals shares in Q2 2025, an estimated $33.5K.
Hexagon Capital Partners first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 19 quarters.
Hexagon Capital Partners's Vertex Pharmaceuticals position peaked at $63.7K in Q2 2024.
1,563 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.